Frankfurt - Delayed Quote EUR

Charles River Laboratories International, Inc. (RV6.F)

221.70 -2.40 (-1.07%)
At close: April 25 at 8:44 AM GMT+2
Loading Chart for RV6.F
DELL
  • Previous Close 224.10
  • Open 221.70
  • Bid 212.30 x 10000
  • Ask 213.60 x 10000
  • Day's Range 221.70 - 221.70
  • 52 Week Range 154.45 - 251.80
  • Volume 15
  • Avg. Volume 7
  • Market Cap (intraday) 11.42B
  • Beta (5Y Monthly) 1.41
  • PE Ratio (TTM) 25.75
  • EPS (TTM) 8.61
  • Earnings Date May 9, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 450.55

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

www.criver.com

20,400

Full Time Employees

December 30

Fiscal Year Ends

Recent News: RV6.F

Performance Overview: RV6.F

Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

RV6.F
3.55%
S&P 500
5.84%

1-Year Return

RV6.F
20.82%
S&P 500
22.03%

3-Year Return

RV6.F
19.09%
S&P 500
20.77%

5-Year Return

RV6.F
83.41%
S&P 500
72.46%

Compare To: RV6.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RV6.F

Valuation Measures

Annual
As of 4/24/2024
  • Market Cap

    11.52B

  • Enterprise Value

    14.13B

  • Trailing P/E

    26.01

  • Forward P/E

    21.93

  • PEG Ratio (5yr expected)

    1.86

  • Price/Sales (ttm)

    2.99

  • Price/Book (mrq)

    3.43

  • Enterprise Value/Revenue

    3.42

  • Enterprise Value/EBITDA

    13.69

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    11.49%

  • Return on Assets (ttm)

    5.19%

  • Return on Equity (ttm)

    14.38%

  • Revenue (ttm)

    4.13B

  • Net Income Avi to Common (ttm)

    474.62M

  • Diluted EPS (ttm)

    8.61

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    276.77M

  • Total Debt/Equity (mrq)

    85.46%

  • Levered Free Cash Flow (ttm)

    218.76M

Research Analysis: RV6.F

Analyst Price Targets

354.00
450.55 Average
221.70 Current
485.00 High
 

Earnings

Consensus EPS
 

Company Insights: RV6.F

People Also Watch